CNT201 in Adult Participants With Dupuytren's Contracture

• [Step1] CNT201 First-dose

  Open-label, single administration of CNT201 at the first dose level.

• [Step1] CNT201 Low-dose

  Open-label, single administration of CNT201 at the low dose level.

• [Step1] CNT201 Intermediate-dose

  Open-label, single administration of CNT201 at the intermediate dose level.

• [Step1] CNT201 High-dose

  Open-label, single administration of CNT201 at the high dose level.

• [Step2] CNT201

  Randomized, double-blind administration of CNT201 for up to 3 treatment cycles.

• [Step2] Placebo

  Randomized, double-blind administration of placebo for up to 3 treatment cycles.

Primary

• Incidence of adverse eventsDay 57

• Change from baseline in systolic and diastolic blood pressureMonth 12

• Change from baseline in pulse rateMonth 12

• Change from baseline in respiratory rateMonth 12

• Change from baseline in body temperatureMonth 12

Secondary

• Proportion of participants achieving clinical improvement (≥50% reduction in contracture from Day 1)Month 12

• Mean percent change in degree of contractureMonth 12

• Time to clinical success (contracture ≤5°)Month 12

• Change in range of motion (full extension, full flexion, and total arc)Month 12

• Participant Global Assessment of Treatment Satisfaction ScoreMonth 12

• Physician Global Assessment of Disease Severity ScoreMonth 12

• Physician Global Assessment of Treatment Satisfaction ScoreMonth 12

• Peak plasma concentration (Cmax) of CNXT1 and CNXT2Day 7